EDEN PRAIRIE, Minn.,
March 2, 2022 /PRNewswire/ --
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, today announced that it
successfully completed initial bench top, long-term stimulation
testing on a novel design of its thin film electrode technology.
The tests measured the electrodes' ability to deliver the number of
electrical stimulation pulses required to meet approximately 5
years of use using an active accelerated aging test model. The
results demonstrated the potential to provide chronic stimulation
at typical stimulation parameters currently used to treat patients
suffering with chronic back pain due to multiple failed back
surgeries.
Dave Rosa, CEO of NeuroOne
commented, "Over the past few years we have been working to develop
the technology for long term use given the large market opportunity
for chronic stimulation technology. The results of both the
long-term recording and stimulation testing demonstrate we are
getting closer to achieving that goal. If we are successful in the
ongoing development and subsequent submission to the FDA this would
enable us to pursue expansion into therapeutic areas such as
long-term stimulation for epilepsy, Parkinson's disease, chronic
back pain due to failed back surgeries and other related
neurological disorders. It may also present opportunities for
licensing the technology to strategic partners for applications
that are outside of our areas of focus. Our initial area of
interest is expected to be spinal cord stimulation for chronic back
pain given the size of the market and the competitive
differentiator we can bring to this market with our unique thin
film, low profile electrode platform."
The Company performed accelerated stimulation testing using
stimulation levels above what is typically used today to treat
patients suffering with chronic back pain due to multiple failed
back surgeries. The tests were conducted by recording the number of
pulses of stimulation each pair of electrode contacts could deliver
before identifying degradation. For a patient with chronic
back pain receiving 16 hours of stimulation per day, the testing
duration and intensity translates to over 5 years of operation or
4-5 years if operating 24 hours per day.
Camilo Diaz-Botia, PhD, Director
of Electrode Development for NeuroOne, said, "We conducted active
accelerated longevity stimulation tests in saline solution, which
is known to represent harsher conditions than saline solutions with
added proteins. After several months of accelerated testing, we
observed that most electrode contacts preserve the ability to
deliver stimulation pulses at levels that would benefit most
patients. We also observed that the electrode material remained
electrochemically stable. Lastly, in agreement with our results on
long-term recording, we again observed that the thin film
insulation performed well during testing."
The Company previously announced successful passive accelerated
testing on electrodes that successfully demonstrated the ability to
record electrical activity for a minimum of five years.
As previously reported, NeuroOne is also advancing a pipeline of
therapeutic electrode technologies for brain tissue ablation,
chronic stimulation use for DBS (deep brain stimulation) and spinal
cord stimulation for chronic back pain. The Company believes these
therapeutic electrode technologies are targeted to addressable
markets of over $10 billion.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information,
visit https://www.n1mtc.com .
Forward Looking Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects the Company's current views about future events and
are subject to known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking
statements by the words or phrases "may," "might," "will," "could,"
"would," "should," "expect," "intend," "plan," "objective,"
"anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue, "focused
on," "committed to" and "ongoing," or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Forward–looking statements may include statements
regarding clinical and pre-clinical testing, NeuroOne's business
strategy, regulatory approvals, market size and potential growth.
Although the Company believes that we have a reasonable basis for
each forward-looking statement, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our expectations of the future, about
which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks that our technology will not
perform as expected based on results of our pre-clinical testing;
uncertainties inherent in the development process of our
technology; risks related to changes in regulatory requirements or
decisions of regulatory authorities; risks that we may not receive
regulatory clearance for long-term use; risks that we may not have
accurately estimated the size and growth potential of the markets
for our technology; and other risks and uncertainties related to
market and other conditions, the impact of general economic,
industry or political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of the podcast and the Company undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-releases-successful-completion-of-long-term-stimulation-tests-for-its-novel-thin-film-platform-electrode-technology-301493777.html
SOURCE NeuroOne Medical Technologies Corporation